Beijing Mabworks Biotech Co., Ltd. announced a private placement of 2,095,558 common shares at a price of CNY 71.58 for gross proceeds of CNY 150,000,041.64 on August 1, 2023. The transaction will include participation from new investor, received CNY Betta Pharmaceuticals Co., Ltd. for 2.91% stake. The transaction has been approved by the 6th session of the company?s 4th directorate and the 4th session of the company?s 4th supervisory board.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
42.84 CNY | -3.08% | +2.66% | -16.90% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-16.90% | 2.48B | |
+7.91% | 72.81B | |
+12.64% | 9.13B | |
-10.56% | 5.13B | |
+58.79% | 4.99B | |
+4.07% | 3.9B | |
-26.13% | 2.32B | |
+19.31% | 2.17B | |
-0.50% | 1.64B | |
+0.07% | 1.59B |
- Stock Market
- Equities
- 300558 Stock
- News Betta Pharmaceuticals Co., Ltd.
- Beijing Mabworks Biotech Co., Ltd. announced that it expects to receive CNY 150.000042 million in funding from Betta Pharmaceuticals Co., Ltd.